Pharmacologically active chemical compounds that were (new drug substance) or are (active pharmaceutical ingredient, API) the components of pharmaceutical formulations or components used in the formulation of pharmaceutical products are identified and quantified through the process of pharmaceutical analysis. The procedure involves numerous pharmaceutical and analytical chemistry fields, making them crucial from a synthetic, medical, or environmental standpoint. Here, the primary focus is on quality control, which ensures that the API and excipients are excellent before the drug is released into the market. To increase the safety of drug therapy, regulatory rules carefully oversee the process to prevent unidentified and possibly hazardous substances, to decrease health risks, and to reduce side effects.

As a result, any API derivatives that do not belong to the chemical class of substances known as pharmacologically active chemicals are referred to as impurities or degradants. The pharmaceutical formulation requires profiling in terms of detection, structure elucidation, and quantitative determination. Due to the expanding pharmaceutical industry and increased oversight of pharmaceutical products, the issue is crucial. These days, one of the most important objectives of pharmacological research is this.

The creation of specialised analytical techniques for the quantification of contaminants and degradants is necessary to comply with regulations. Despite the use of sophisticated technologies, the structural closeness and physical similarity of certain chemical entities make pharmaceutical analysis highly challenging. Thus, it is essential to propose fresh ideas that enable us to simplify analysis and solve current issues. In this situation, molecularly imprinted polymers (MIPs) might be a category of alluring contenders for picky materials that live up to expectations. However, MIPs have mostly caught people's interest as sorbents or stationary phases for separation reasons. These materials have also found applications as sensors and prospective drug delivery systems.

Several articles have demonstrated the potential of MIPs for the efficient elimination of hazardous contaminants. The identification and assessment of MIPs for the selective elimination of potentially genotoxic derivatives of aminopyridine contaminants from pharmaceuticals have been described by Kecili and coworkers. Using pre-existing MIP resin libraries, screening tests were conducted in this case to find polymers selective for certain impurities when model pharmaceutical substances were present. In addition, Esteves and colleagues have improved MIP sorbent to remove aminopyridine contaminants from API in the post-reaction stream. The MIP was created and studied by Szekely and colleagues to remove hazardous 1,3-diisopropylurea from API solutions as well as acetamide and arylsulfonate contaminants from crude medicines.

Journal of Clinical Nephrology and Therapeutics is an open access, peer reviewed journal committed to publishing articles on all aspects of the advances in clinical research in Nephrology, Diabetic nephropathy, Pediatric nephrology, Renal physiology, Transplant medicine, Immunosuppression management, Intensive care nephrology, Ischemic nephropathy, Perioperative medicine etc.

You may submit manuscripts online at: clinnephrol@emedscholar.com

Regards,

Journal Coordinator

Journal of Clinical Nephrology and Therapeutics